Zhang Xuesong, Zhang Ying, Hu Yuanhui
Department of Cardiovascular Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Department of Cardiovascular Diseases, Beijing Hepingli Hospital, Beijing, China.
Front Cardiovasc Med. 2022 Nov 3;9:1039348. doi: 10.3389/fcvm.2022.1039348. eCollection 2022.
Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), is recommended for all patients with Heart failure (HF) to reduce the risk of Cardiovascular death, hospitalization, and HF exacerbation. Qualitative and quantitative evaluation was conducted by searching relevant literatures of EMPA for Heart Failure from 2013 to 2022, and visual analysis in this field was conducted.
The data were from the Web of Science Core Collection database (WOSCC). The bibliometric tools, CiteSpace and VOSviewer, were used for econometric analysis to probe the evolvement of disciplines and research hotspots in the field of EMPA for Heart Failure.
A total of 1461 literatures with 43861 references about EMPA for Heart Failure in the decade were extracted from WOSCC, and the number of manuscripts were on a rise. In the terms of co-authorship, USA leads the field in research maturity and exerts a crucial role in the field of EMPA for Heart Failure. Multidisciplinary research is conducive to future development. With regards to literatures, we obtained 9 hot paper, 93 highly cited literatures, and 10 co-cited references. The current research focuses on the following three aspects: EMPA improves left ventricular remodeling, exert renal protection, and increases heart rate variability.
Based on methods such as bibliometrics, citation analysis and knowledge graph, this study analyzed the current situation and trend of EMPA for Heart Failure, sorted out the knowledge context in this field, and provided reference for current and future prevention and scientific research.
恩格列净（EMPA）是一种钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i），推荐用于所有心力衰竭（HF）患者，以降低心血管死亡、住院和HF恶化的风险。通过检索2013年至2022年关于EMPA治疗心力衰竭的相关文献进行定性和定量评估，并对该领域进行可视化分析。
数据来自科学网核心合集数据库（WOSCC）。使用文献计量工具CiteSpace和VOSviewer进行计量分析，以探究EMPA治疗心力衰竭领域的学科演变和研究热点。
从WOSCC中提取了过去十年中关于EMPA治疗心力衰竭的1461篇文献，共43861条参考文献，且手稿数量呈上升趋势。在合著方面，美国在研究成熟度方面领先该领域，在EMPA治疗心力衰竭领域发挥着关键作用。多学科研究有利于未来发展。关于文献，我们获得了9篇热点论文、93篇高被引文献和10篇共被引参考文献。当前研究集中在以下三个方面：EMPA改善左心室重构、发挥肾脏保护作用以及增加心率变异性。
本研究基于文献计量学、引文分析和知识图谱等方法，分析了EMPA治疗心力衰竭的现状和趋势，梳理了该领域的知识脉络，为当前及未来的预防和科研工作提供参考。
